Company Dynamic

PPG Industries released its financial results for the fourth quarter and the entire year of 2024, revealing a net sales figure of $15.845 billion, which represents a 2% decline compared to the previous year.

AkzoNobel released its financial performance report for the fiscal year 2024, revealing a sales figure of €10.711 billion (approximately $11.618 billion or ¥827.4 billion), which remained relatively stable compared to the previous year.

LANXESS is about to launch a highly sustainable variant of its Bayferrox iron oxide yellow pigment.

• LANXESS
• Scopeblue
• Bayferrox iron oxide yellow pigment

On February 3, Sanofi announced the acquisition of 2.3% of the shares from long-term shareholder L'Oréal. The transaction is part of Sanofi's share repurchase plan.

• Sanofi
• L'Oréal

On January 30, Roche announced its financial results for 2024, reporting total revenue of CHF 60.495 billion (approximately $66.4 billion with a conversion rate of 1 CHF = 1.0981 USD), representing a 7% year-on-year growth. However, net income declined to

On January 30, Dow Inc. announced two significant strategic measures focused on layoffs and reducing capital expenditures. The company aims to achieve annual cost savings of $1 billion (approximately 72.5 billion RMB) through various initiatives.

On February 4, Merck & Co. announced its 2024 financial results, revealing total revenue of $64.168 billion, marking a 7% increase year-on-year. The pharmaceutical segment alone generated $57.400 billion, also reflecting a 7% growth.

On January 22, Johnson & Johnson announced its Q4 2024 financial results, revealing total annual revenue of $88.8 billion, representing a 4.3% increase year-on-year.

On January 10, 2025, Mediar Therapeutics announced a significant global licensing agreement with pharmaceutical giant Eli Lilly and Company to advance MTX-463 into a Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).

Repsol’s Board of Directors approved the investment in Ecoplant, adding to the solution to reduce CO2 emissions in the transport sector while promoting a circular economy.

• Repsol

Brenntag announces the expansion of its existing distribution agreement in the US with Kao Chemicals Europe, SLU.

• Brenntag
• Kao

BASF has developed a certified industrially compostable biopolymer for the manufacture of black and white plant clips. This is for the sustainable cultivation of greenhouse fruits and vegetables.

• BASF
• clips
• biodegrade

Kering has completed the sale of its luxury outlet business, The Mall Luxury Outlets, to American real estate giant Simon.

• Kering
• The Mall Luxury Outlets
• Simon

Evonik and Oerlikon Barmag have announced a collaboration to promote the chemical recycling of polyethylene terephthalate (PET) waste.

• Evonik
• Oerlikon

BASF, Germany's largest chemical manufacturer, reported lower-than-expected annual profits on the 24th due to impairment of battery materials in its surface technology division and restructuring costs.

• BASF

BASF’s Personal Care business has launched a new ingredient, VitaGuard A, to meet the continued demand for retinol and strengthen its position as a cosmetic staple. This latest innovation is based on the encapsulation of free retinol.

• BASF
• personal care
• VitaGuard A
• retinol

In a decisive move to ensure food safety, the United Arab Emirates (UAE) has intensified inspections on food items containing synthetic food dyes. This action follows a recent ban by the United States on Red No. 3, an artificial color commonly used to imp

Recently, Sinopec Chuanwei Chemical successfully conducted its first trial run of the 60,000 tons/year VAE (Vinyl Acetate-Ethylene Copolymer Emulsion) expansion project, producing qualified products on its initial feed. With this achievement, Chuanwei Che

On January 22, Evonik announced the strategic merger of its silica and silane business lines into a new company called Smart Effects, had be launched on January 1, 2025. This new entity will employ 3,500 individuals globally and will form part of Evonik's

AbbVie and Neomorph have announced a strategic partnership and option-to-license agreement aimed at creating a new class of treatments using molecular glue degraders.